TrialBlood cancer journal2024

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Natalie S Callander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.